Expert Opinion on Investigational Drugs, Volume 31, Issue 9 (2022)

Browse this journal
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Investigational Drugs, Volume 31, Issue 9 (2022)

See all volumes and issues
Vol 33, 2024 Vol 32, 2023 Volume 31, 2022 Vol 30, 2021 Vol 29, 2020 Vol 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Vol 22, 2013 Vol 21, 2012 Vol 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994
Download citations Download PDFs Download issue

Editorial

Editorial
CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors
Christopher Moertel, Francisco Martinez-Puerta, Grace G. Elizabeth Pluhar, Maria Graciela Castro & Michael Olin
Pages: 875-879
Published online: 03 Aug 2022
First Page PreviewforCD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors | Full Text | References | PDF (2.4 MB) | EPUB
  • 1104 Views
  • 1 CrossRef citations
  • 0Altmetric
Free Access
Editorial
Pure red cell aplasia after hematopoietic stem cell transplantation - experimental therapeutic approaches
Anh Khoi Vo, Tor Hervig & Håkon Reikvam
Pages: 881-884
Published online: 12 Sep 2022
First Page PreviewforPure red cell aplasia after hematopoietic stem cell transplantation - experimental therapeutic approaches | Full Text | References | PDF (752.8 KB) | EPUB
  • 1738 Views
  • 0 CrossRef citations
  • 0Altmetric
Free Access

Perspective

Article
Immune checkpoint inhibitors for the treatment of sepsis:insights from preclinical and clinical development
Mario Rienzo, Tomasz Skirecki, Guillaume Monneret & Jean-François Timsit
Pages: 885-894
Published online: 18 Aug 2022
AbstractforImmune checkpoint inhibitors for the treatment of sepsis:insights from preclinical and clinical development | Full Text | References | PDF (827.1 KB) | EPUB
  • 549 Views
  • 5 CrossRef citations
  • 0Altmetric

Review

Review
Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials
Fabio Conforti, Laura Pala, Tommaso De Pas, Yongfeng He & Giuseppe Giaccone
Pages: 895-904
Published online: 19 Aug 2022
AbstractforInvestigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials | Full Text | References | PDF (365 KB) | EPUB
  • 219 Views
  • 3 CrossRef citations
  • 0Altmetric
Review
Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials
Bilal Asif & Christopher Koh
Pages: 905-920
Published online: 01 Oct 2021
AbstractforHepatitis D virus (HDV): investigational therapeutic agents in clinical trials | Full Text | References | PDF (2.5 MB) | EPUB
  • 393 Views
  • 5 CrossRef citations
  • 0Altmetric
Review
Giant cell arteritis: what is new in the preclinical and early clinical development pipeline?
Patricia Harkins & Richard Conway
Pages: 921-932
Published online: 30 Jun 2021
AbstractforGiant cell arteritis: what is new in the preclinical and early clinical development pipeline? | Full Text | References | PDF (1.8 MB) | EPUB
  • 430 Views
  • 3 CrossRef citations
  • 0Altmetric
Review
Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition
Xianan Guo, Huihui Chen, Yunxiang Zhou, Lu Shen, Shijie Wu & Yiding Chen
Pages: 933-944
Published online: 07 Jul 2022
AbstractforCyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition | Full Text | References | PDF (907.2 KB) | EPUB
  • 524 Views
  • 0 CrossRef citations
  • 0Altmetric

Systematic Review

Systematic Review
Investigational drugs for the treatment of olfactory dysfunction
Arianna Di Stadio, Cinzia Severini, Andrea Colizza, Marco De Vincentiis & Ignazio La Mantia
Pages: 945-955
Published online: 19 Aug 2022
AbstractforInvestigational drugs for the treatment of olfactory dysfunction | Full Text | References | PDF (2.3 MB) | EPUB
  • 136 Views
  • 2 CrossRef citations
  • 0Altmetric

Meta-Analysis

Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participants
Zonglin Li, Chu Lin, Jinyu Zhou, Xiaoling Cai, Xingyun Zhu, Suiyuan Hu, Fang Lv, Wenjia Yang & Linong Ji
Pages: 957-964
Published online: 22 Aug 2022
AbstractforDipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participants | Full Text | References | PDF (507.1 KB) | EPUB | Supplemental
  • 301 Views
  • 0 CrossRef citations
  • 0Altmetric

Original Research

Article
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST)
Christopher Wynne, Christian Schwabe, Charlotte Lemech, Heimo Stroissnig, Roshan Dias, Joanna Sobierska, Eric Guenzi, Hendrik Otto, Abid Sattar, Richard Kay, Halimu N. Haliduola & Fausto Berti
Pages: 965-976
Published online: 10 Feb 2022
AbstractforA randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST) | Full Text | References | PDF (749.9 KB) | EPUB | Supplemental
  • 2751 Views
  • 6 CrossRef citations
  • 0Altmetric
Open Access
Article
A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers
Yue Hu, Hong Zhang, Xiaojiao Li, Jiajia Mai, Lizhi Yang, Jie Yan, Ying Li, Jingchao Sun, Wenjie Xu, Shiying He, Jinfeng Li & Min Wu
Pages: 977-985
Published online: 08 Nov 2021
AbstractforA randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers | Full Text | References | PDF (884.5 KB) | EPUB
  • 214 Views
  • 1 CrossRef citations
  • 0Altmetric

Explore articles

Explore the most recently published articles

Inflammation and Huntington’s disease- a neglected therapeutic target?
Sophie E. Field et al.
Review Article | Published online: 17 May 2024
Drugs in preclinical and early clinical development for the treatment of Chagas´s disease: the current status
Fernanda Karoline Vieira da Silva Torchelsen et al.
Review Article | Published online: 14 May 2024
Emerging therapies for overactive bladder: preclinical, phase I and phase II studies
Samantha Gibson et al.
Review Article | Published online: 9 May 2024
Frontotemporal dementia: from genetics to therapeutic approaches
Francesca R. Buccellato et al.
Review Article | Published online: 9 May 2024
Open Access
View all latest articles